miscellaneous for COVID-19: living meta-analysis of clinical studies

Table Graph

miscellaneous - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.56 [0.26, 1.21]	< 1	0%	7 studies (7/-)	92.9 %	some concern	not evaluable	moderate	crucial	-
death or transfer to ICU	0.55 [0.26, 1.17]	< 1	0%	1 study (1/-)	93.9 %	some concern	not evaluable	moderate	crucial	-
deaths	0.49 [0.22, 1.08]	< 1	0%	7 studies (7/-)	96.2 %	some concern	not evaluable	moderate	crucial	-
deaths (time to event analysis only)	0.35 [0.06, 1.96]	< 1	52%	2 studies (2/-)	88.4 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	0.33 [0.03, 3.75]	< 1	0%	2 studies (2/-)	81.2 %	some concern	not evaluable	moderate	important	-
clinical improvement	1.29 [0.99, 1.67]	> 1	14%	5 studies (5/-)	97.2 %	some concern	not evaluable	moderate	important	-
clinical improvement (14-day)	10.27 [1.17, 90.18]	> 1	0%	1 study (1/-)	98.2 %	some concern	not evaluable	moderate	important	-
clinical improvement (21-day)	2.09 [0.04, 119.96]	> 1	0%	1 study (1/-)	63.7 %	some concern	not evaluable	moderate	important	-
clinical improvement (28-day)	2.98 [0.59, 15.15]	> 1	0%	3 studies (3/-)	90.6 %	some concern	not evaluable	moderate	important	-
clinical improvement (7-day)	6.72 [1.50, 30.07]	> 1	0%	1 study (1/-)	99.4 %	some concern	not evaluable	moderate	important	-
clinical improvement (time to event analysis only)	1.14 [0.83, 1.57]	> 1	0%	1 study (1/-)	79.0 %	some concern	not evaluable	moderate	important	-
hospital discharge	10.00 [1.03, 97.50]	> 1	0%	1 study (1/-)	97.5 %	some concern	not evaluable	moderate	important	-
mechanical ventilation	0.52 [0.13, 2.13]	< 1	38%	5 studies (5/-)	81.6 %	some concern	serious	moderate	important	-
mechanical ventilation (time to event analysis only)	0.69 [0.14, 3.42]	< 1	0%	1 study (1/-)	67.5 %	some concern	not evaluable	moderate	important	-
viral clearance by day 14	1.00 [0.03, 34.67]	> 1	0%	1 study (1/-)	50.0 %	some concern	not evaluable	moderate	important	-
ICU admission	0.80 [0.34, 1.90]	< 1	0%	1 study (1/-)	69.4 %	some concern	not evaluable	moderate	non important	-
recovery	1.24 [0.69, 2.23]	> 1	35%	4 studies (4/-)	76.3 %	some concern	not evaluable	moderate	non important	-
safety endpoints 00
related AE (TRAE)	1.26 [0.14, 11.07]	< 1	0%	2 studies (2/-)	41.9 %	some concern	not evaluable	moderate	important	-
serious adverse events	0.61 [0.08, 4.90]	< 1	73%	3 studies (3/-)	67.9 %	some concern	not evaluable	moderate	important	-
adverse events	0.73 [0.44, 1.21]	< 1	3%	6 studies (6/-)	89.2 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

miscellaneous - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00